Company news
Maxcyte, Inc. (NASDAQ:MXCT) news
Every Maxcyte, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
August 19, 2026
MaxCyte Reports Second Quarter 2026 Financial Results
August 12, 2026
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
July 21, 2026
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
July 15, 2026
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
May 12, 2026
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
April 29, 2026
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2026
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
March 24, 2026
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
March 23, 2026
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
February 24, 2026
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
February 23, 2026
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
MaxCyte Announces Planned CFO Transition in 2026
November 12, 2025
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 12, 2025
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 5, 2025
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
October 8, 2025
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
October 6, 2025
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
September 22, 2025
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
August 6, 2025
MaxCyte Signs Platform License Agreement with Adicet Bio
August 4, 2025
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
July 31, 2025
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
July 9, 2025
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan
July 1, 2025
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
June 11, 2025
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
May 7, 2025
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
April 10, 2025
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
March 11, 2025
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
February 12, 2025
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
January 30, 2025
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
January 13, 2025
MaxCyte Announces Retirement of Board Member Art Mandell
December 23, 2024
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
December 9, 2024
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
November 13, 2024
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
November 6, 2024
MaxCyte Appoints Cynthia Collins to its Board of Directors
October 15, 2024
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
October 10, 2024
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
September 16, 2024
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
August 6, 2024
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
May 22, 2024
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
May 7, 2024
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
April 10, 2024
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
April 2, 2024
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
March 12, 2024
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
March 4, 2024
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
February 9, 2024
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigationa...
January 30, 2024
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
January 23, 2024
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
January 8, 2024
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
January 2, 2024
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
December 11, 2023